• Western blot analysis of PLMN (heavy chain A short form, Cleaved-Val98) Antibody. The lane on the right is blocked with the PLMN (heavy chain A short form, Cleaved-Val98) peptide.
  • Western blot analysis of various cells using Cleaved-Plasminogen HC A short form (V98) Polyclonal Antibody

Anti-Cleaved-PLG-V98 antibody (79-128 aa) (STJ90102)

SKU:
STJ90102

Current Stock:
Host: Rabbit
Applications: WB/ELISA
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Cleaved-Plasminogen-V98 (79-128 aa) is suitable for use in Western Blot and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
ELISA 1:10000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: PLG
Gene ID: 5340
Uniprot ID: PLMN_HUMAN
Immunogen Region: 79-128 aa
Specificity: Cleaved-Plasminogen HC A short form (V98) Polyclonal Antibody detects endogenous levels of fragment of activated Plasminogen HC A short form protein resulting from cleavage adjacent to V98.
Immunogen: The antiserum was produced against synthesized peptide derived from the human PLMN at the amino acid range 79-128
Post Translational Modifications N-linked glycan contains N-acetyllactosamine and sialic acid. O-linked glycans consist of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity). In the presence of the inhibitor, the activation involves only cleavage after Arg-580, yielding two chains held together by two disulfide bonds. In the absence of the inhibitor, the activation involves additionally the removal of the activation peptide.
Function Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells. Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo. (Microbial infection) ENO/enoloase from parasite P.falciparum (strain NF54) interacts with PLG present in the mosquito blood meal to promote the invasion of the mosquito midgut by the parasite ookinete. The catalytic active form, plasmin, is essential for the invasion of the mosquito midgut. (Microbial infection) Binds to OspC on the surface of B.burgdorferi cells, possibly conferring an extracellular protease activity on the bacteria that allows it to traverse host tissue.
Protein Name Plasminogen Cleaved Into - Plasmin Heavy Chain A - Activation Peptide - Angiostatin - Plasmin Heavy Chain A - Short Form - Plasmin Light Chain B
Database Links Reactome: R-HSA-114608
Reactome: R-HSA-1474228
Reactome: R-HSA-1592389
Reactome: R-HSA-186797
Reactome: R-HSA-381426
Reactome: R-HSA-75205
Cellular Localisation Secreted
Locates To The Cell Surface Where It Is Proteolytically Cleaved To Produce The Active Plasmin
Interaction With Hrg Tethers It To The Cell Surface
Alternative Antibody Names Anti-Plasminogen Cleaved Into - Plasmin Heavy Chain A - Activation Peptide - Angiostatin - Plasmin Heavy Chain A - Short Form - Plasmin Light Chain B antibody
Anti-PLG antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance